Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 17/20 | 0.53 |
| ▸ | HTR2A | P28223 | 15/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998864 | 0.87 | SLC6A4 (0.54) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000269 | 0.85 | SLC6A4 (0.39) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5502146 | 0.83 | SLC6A4 (0.59) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000223 | 0.78 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL5503981 | 0.78 | SLC6A4 (0.79) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000140 | 0.77 | HTR2A (0.65) | SLC6A4KCNH2HTR2A | |
| SCHEMBL6000243 | 0.74 | SLC6A4 (0.54) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000299 | 0.74 | HTR2A (0.65) | SLC6A4KCNH2HTR2A | |
| SCHEMBL5999623 | 0.72 | SLC6A4 (0.57) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 | |
| SCHEMBL6000033 | 0.72 | SLC6A4 (0.48) | SLC6A4KCNH2HTR2ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | SLC6A4 150/4885KCNH2 2331/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.